Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 05, 2016 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the 15th Annual Needham Healthcare Conference being held at The Westin NY Grand Central Hotel in New York, New York from April 12-13, 2016. Ocera’s presentation will take place on Wednesday, April 13th, 2016 at 3:40 PM Eastern Time.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 90 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
OCRX-G
Contact:
Susan Sharpe
Ocera Therapeutics, Inc.
[email protected]
919-328-1109
